Pharma Mar, S.A. (PHM.MC)
Develops cancer drugs derived from marine organisms and gene-silencing treatments.
78.60+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-0.8%
The outlook
Pharma Mar trades at 78.6 with analyst consensus leaning toward Buy, though the stock sits below its 50- and 200-day moving averages. The price is positioned in the lower third of its 52-week range, while the average analyst target implies roughly 33% upside from current levels. The overall outlook remains neutral despite the bullish consensus.
What’s behind the score
Analyst consensusBuy — 1.6 avg of 9 analysts
Price trendBelow its 50- & 200-day averages
52-week range35% of the way from its 52-week low to high
Price targetAvg target +33% vs current price
Analyst price target
~12-month · 9 analysts104.39average target+32.8% vs now
Now 78.60
Low 85.50High 125.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.36B
52-wk high
105.20
52-wk low
64.00
50-day avg
82.49
200-day avg
82.00
Trailing P/E
17.0